MBK Partners and Young Poong Refute Korea Zinc’s Baseless Claims
Reading Time: 2 minutes Seoul, South Korea: MBK Partners has clarified its position on a matter involving Korea Zinc, stating that the company is making claims that are far from reality. The matter dates back to May 2022, when a person known to be close
Curtiss-Wright and Sintavia Deliver First Submarine Component Utilizing an Additively Manufactured Impeller to be Installed in a U.S. Navy Vessel
Reading Time: 3 minutes Cheswick, Pa., United States: Curtiss-Wright’s EMS Division today announced that it has delivered the first submarine component with an additively manufactured (AM) impeller that will be installed in a U.S. Navy vessel. Curtiss-Wright’s Engineered Pump Division (EPD) in
An Alliance Launched to Advance India’s New-Age Economy
Reading Time: 4 minutes Delhi, India: Startup Policy Forum (SPF) is a first-of-its-kind industry alliance dedicated to representing and advancing India’s new-age economy. It will serve as a vital link between startup founders and policymakers. SPF brings together 30 of India’s leading
Zwipe publishes prospectus related to the rights issue
Reading Time: 5 minutes THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY
SyntheticMR AB (publ) appoints Vedran Beglerbegovic as Acting CEO for SyntheticMR
Reading Time: < 1 minute The board of SyntheticMR AB (publ) has today decided to appoint Vedran Beglerbegovic as Acting CEO with immediate effect, due to the current CEO, Ulrik Harrysson, being on sick leave indefinitely. Vedran Beglerbegovic, who currently holds the position of COO
Leqembi® approved in Mexico – BioArctic
Reading Time: 4 minutes Stockholm, Sweden, December 5, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD)[1].
#24-417 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
FISKARS CORPORATION: ACQUISITION OF OWN SHARES 04.12.2024
Reading Time: < 1 minute Stock Exchange Release 04.12.2024 at 18:30 EET/EEST FISKARS CORPORATION: ACQUISITION OF OWN SHARES 04.12.2024 Date 04.12.2024 Exchange transaction Buy Share class FSKRS Amount 2,000 Average price/share 14.8068 EUR Highest price/share 14.9600 EUR Lowest price/share
ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 04.12.2024
Reading Time: < 1 minute ALEXANDRIA GROUP OYJ NOTIFICATION 04.12.2024 at 18:30 EET ALEXANDRIA GROUP OYJ: ACQUISITION OF OWN SHARES 04.12.2024 Date 04.12.2024 Exchange transaction Buy Share class ALEX Amount 69 Average price/share 8.5500 EUR Highest
Nordea Bank Abp: Repurchase of own shares on 04.12.2024
Reading Time: < 1 minute Nordea Bank AbpStock exchange release – Changes in company’s own shares04.12.2024 at 22.30 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 04.12.2024 completed repurchases of own shares (ISIN: FI4000297767) as follows: Trading venue (MIC Code) Number of shares Weighted average